Andrew Callos - 02 Feb 2026 Form 4 Insider Report for CYTOKINETICS INC (CYTK)

Signature
/s/ John O. Faurescu, attorney-in-fact for Mr. Callos
Issuer symbol
CYTK
Transactions as of
02 Feb 2026
Net transactions value
-$21,680
Form type
4
Filing time
02 Feb 2026, 16:40:38 UTC
Previous filing
05 Jan 2026
Next filing
05 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Callos Andrew EVP, Chief Commercial Officer 350 OYSTER POINT BLVD, SOUTH SAN FRANCISCO /s/ John O. Faurescu, attorney-in-fact for Mr. Callos 02 Feb 2026 0001852129

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CYTK Common Stock Options Exercise $33,340 +886 +1.8% $37.63 51,326 02 Feb 2026 Direct
transaction CYTK Common Stock Sale $55,021 -886 -1.7% $62.10 50,440 02 Feb 2026 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CYTK Incentive Stock Option (Right to Buy) Options Exercise $0 -886 -50% $0.000000 886 02 Feb 2026 Common Stock 886 $37.63 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable over 4 years, with shares divided into equal monthly installments, such that the option shall be 100% vested four years from the date of grant.